Neuroendocrine Tumors

Any Differentiation

Locally Advanced, 2nd line +

Liver-Dominant Metastatic Disease

VAR0149
Phase II/III Hu5F9-G4 in Combination w/ Cetuximab in Solid Tumors & Advanced Colorectal Cancer
PI: Fisher Forty Seven Inc

GI0013
Phase I Personalized Live Attenuated Live Attenuated Double Deleted Listeria Monocytogenes ImmunoTx in Colorectal Cancer
PI: Fisher Aduro Biotech Inc

ECOG-ACRIN-00161
Phase II MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
PI: Fisher ECOG-ACRIN

NET0024
Phase I XmAb18087 in Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
PI: Kunz ECOG-ACRIN

Well Differentiated

Anti-proliferative

ECOG-ACRIN-EA2142
Phase II Cisplatin & Etoposide vs Temozolomide &Capecitabine in Gastroenteropancreatic Neuroendocrine Ca
PI: Kunz ECOG-ACRIN

2nd Line

VAR0179
A Randomized, Controlled Trial Examining the Use of The "Serious Illness Conversation Guide" (SICG) in Patients with Advanced Gastro-Intestinal Cancers.
PI: Johnson Sponsor: Stanford

Poorly Differentiated

LUN0084
Phase II RRX-001 in SCLC / NSCLC / Neuroendocrine Carcinoma or Ovarian Cancer (Including MMT)
PI: Padda EpicenRx, Inc

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu